Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service incontinence, prolapse & sacral neuromodulation cases in Maine: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (219 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 2 | 219 | 39% |
| 2020 | 3 | 152 | 46% |
| 2021 | 1 | 139 | 51% |
| 2022 | 0 | 102 | 56% |
| 2023 | 1 | 101 | 59% |
| 2024 | 2 | 101 | 62% |
| 2025 from claims | – | 42 34–49 | 63% |
| 2026 forecast | – | 43 34–54 | 63% |
| 2027 forecast | – | 43 32–57 | 64% |
| 2028 forecast | – | 43 31–60 | 64% |
| 2029 forecast | – | 43 30–62 | 65% |
| 2030 forecast | – | 44 29–65 | 65% |
Slings, artificial sphincter, colpopexy, sacral neuromodulation, penile prosthesis. Professional codes (what the surgeon bills): CPT 57288, 53440, 53445, 57425, 57282, 57283, 64581, 64590, 54405.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Maine; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 38 | 3,138−0.8%/yr | −0.8%/yr | 1.7 | 8% | 3,860 in 2030+3.5%/yr |
| Pennsylvania | 45 | 2,928+2.4%/yr | +2.4%/yr | 2.1 | 8% | 3,450 in 2030+2.8%/yr |
| Massachusetts | 30 | 1,885+3.7%/yr | +3.7%/yr | 2.0 | 1% | 2,140 in 2030+2.1%/yr |
| New Jersey | 26 | 1,784−4.1%/yr | −4.1%/yr | 1.7 | 9% | 1,880 in 2030+0.9%/yr |
| Connecticut | 11 | 668+0.3%/yr | +0.3%/yr | 2.0 | 0% | 740 in 2030+1.6%/yr |
| New Hampshire | 5 | 344−2.3%/yr | −2.3%/yr | 1.5 | 0% | 460 in 2030+4.9%/yr |
| Rhode Island | 2 | 201+0.4%/yr | +0.4%/yr | 2.2 | 31% | 130 in 2030−7.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 11 | 5,521+56%/yr | +56%/yr | 35.47.6× | 0% | 540 in 2030−32%/yr |
| BPH procedures | 6 | 406−1.3%/yr | −1.3%/yr | 2.60.6× | 0% | 340 in 2030−2.8%/yr |
| Hysterectomy, hysteroscopy & ablation | 3 | 290−6%/yr | −6%/yr | 2.00.6× | 7% | 370 in 2030+4%/yr |
Incontinence, prolapse & sacral neuromodulation in every state, and its device makers · Every procedure market in Maine · Every state · Compare with New York
Boston Scientific leads with 54% of company spending on these surgeons in 2025, +27 pts on 2024.
In 2025, 5 companies reported engagement with Maine’s surgeons worth $99K in consulting, speaking, meals and travel tied to these products, about $49K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 46 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.